Chitosan in regenerative medicine: a translational perspective on biomaterial design Adrianna Banach-Kopeć, Lisa Gugler, Karol Staszczyk, Szymon Mania, Agnes S. Klar, Robert Tylingo Abstract Chitosan is an aminopolysaccharide platform with broad relevance to regenerative medicine because its charge density, solubility, degradation, processability, and biological interactions can be adjusted through source selection, deacetylation chemistry, molecular-weight control, derivatization, and formulation. However, this tunability is accompanied by substantial source- and process-dependent variability, which represents a central translational challenge: materials labelled as chitosan can differ markedly in degree of deacetylation, molecular weight, pattern of acetylation, polydispersity, purity, endotoxin and β-glucan burden, residual reagents, sterilization history, and final architecture. This review synthesizes chitosan regenerative biomaterials from a translational design perspective. We examine raw-material provenance, crustacean and fungal sources, extraction and deacetylation routes, physicochemical determinants, medical-grade purity requirements, host-biointerface mechanisms, antimicrobial activity, scaffolds, hydrogels, coatings, bioinks, polymer composites, and functionalization with growth factors, drugs, peptides, and extracellular vesicles. We also address ethical, cell-related, regulatory, and manufacturing issues that arise when chitosan is combined with animal-derived inputs, antibiotics, growth factors, living cells, or extracellular-vesicle preparations. Across applications, the evidence indicates that chitosan should not be treated as a universally biocompatible, universally antimicrobial, or intrinsically regenerative polymer. Rather, it is a tunable, formulation-dependent biomaterial platform whose performance depends on defined chemical attributes, exposure route, biological context, and clinically relevant comparators. Translation will require standardized reporting of degree of deacetylation, molecular weight, acetylation pattern, purity, endotoxin and β-glucan controls, sterilization effects, degradation, release kinetics, post-release bioactivity, and product-specific biological evaluation. Regulatory-aware design, reproducible manufacturing, and mechanism-linked potency assays are essential for moving chitosan-based regenerative systems from promising preclinical constructs toward credible clinical products. Introduction Regenerative medicine integrates cell biology, materials engineering, and targeted therapies to restore tissue and organ function beyond what transplantation can offer. Tissue engineering, which combines cells, biodegradable scaffolds, and growth factors, represents one of its central pillars (; ; ; ). The driving need is demographic and structural: an aging population and rising chronic disease increase the number of patients with tissue damage, while donor organs remain scarce and long-term care for organ failure burdens health systems (; ). Contemporary translation therefore demands more than biological efficacy: reproducibility, manufacturability at scale, and compliance with medical-device and advanced-therapy regulatory frameworks are equally decisive (; ). Accordingly, this review adopts a translational design perspective, treating biomaterials not as inert carriers but as active participants in regeneration whose properties can be tuned to steer repair (; ). Regenerative medicine and the role of biomaterials Reconstructing living tissue depends on appropriate combinations of cells, biological signals, and biomaterial scaffolds (; ). Scaffolds such as porous sponges, membranes, and hydrogels provide a structural framework for cell colonization, deliver bioactive cues, and create a microenvironment conducive to regeneration. An important shift in the field has been the evolution from inert support matrices to “smart” materials that dynamically interact with surrounding tissue by presenting ligands, releasing growth factors at controlled rates, or responding to pH or temperature (; ; ). Such active biomaterials can accelerate angiogenesis, direct stem-cell differentiation, and modulate inflammation, acting simultaneously as extracellular matrix (ECM)-mimicking physical supports and as bioactive modulators of healing (; ; ). This dual role increasingly includes controlled bioactive-molecule delivery, immunomodulation, antimicrobial action, and matrix remodeling, including implants with antibacterial or immunomodulatory coatings that prevent infection and steer the host response toward regeneration rather than rejection (; ). These principles are summarized schematically in . This narrative critical review synthesizes recent advances in chitosan-based biomaterials from a translational design perspective rather than as a systematic survey. We focus on the relationships between chitosan source, DD, MW, purity, and processing route, on the one hand, and biological functionality and clinical translation potential, on the other, while highlighting key performance-defining features across different formats, including porosity and stiffness in scaffolds, in situ gelation in hydrogels, controlled release in nanoscale systems, and printability in bioinks. We also identify the principal remaining gaps: standardized characterization, better reporting of material parameters, control of purity and endotoxin, storage stability, and optimized formulations for regenerative medicine and 3D bioprinting. Why chitosan? Among the many biomaterials investigated for regenerative medicine, chitosan has attracted particular attention because of its unique combination of properties (). Chitosan is a natural polysaccharide obtained by deacetylation of chitin, one of the most abundant biopolymers in nature, with commercial chitin being predominantly sourced from crustacean shells (). In defined, soluble, and appropriately protonated formulations, it offers favorable cytocompatibility, biodegradation, and low toxicity (); antibacterial activity against Gram-positive and Gram-negative bacteria, attributed to its protonated amino groups disrupting microbial membranes (); and hemostatic activity through erythrocyte aggregation and platelet adhesion/activation, which has supported its use in wound dressings and hemostatic materials (; ). As detailed in later sections, these properties are formulation- and context-dependent rather than intrinsic to chitosan as a chemical entity. Together with its processability, these context-specific properties make chitosan attractive for wound healing, tissue engineering, and regenerative medicine (; ). Importantly, regulatory recognition for selected uses, including GRAS status in specific contexts, does not constitute general approval for implantable or broader clinical applications, which require separate biological, preclinical, and regulatory evaluation. Chitosan’s intrinsic chemical modifiability makes it remarkably versatile in biomaterial design (); its multifunctional character and the parameters that determine its biomedical performance are summarized in . The glucosamine-based backbone permits adjustment of the degree of deacetylation (DD), introduction of functional groups, crosslinking, and derivatization (), allowing fine-tuning of key physicochemical parameters:Surface charge: higher deacetylation yields more protonated amino groups, affecting interactions with cells and proteins ();Solubility: native chitosan dissolves only in acid, but modifications such as quaternization confer solubility at neutral pH ();Network-forming ability: chitosan forms networks via chemical crosslinking (e.g., genipin, aldehydes) and ionic gelation with multivalent polyanions such as tripolyphosphate, with properties depending on DD, molecular weight (MW), pH, concentration, and crosslinker (; ; ). This tunability underlies chitosan’s many biomaterial forms, but safety and compatibility remain product- and context-specific, and effective clinical translation requires early standardization, rigorous quality control of natural variability (MW, DD, purity), safety vetting of any new modification, and integration of polymer chemistry, cell biology, and tissue engineering (; ). The spectrum of chitosan biomaterial forms Chitosan’s processability allows fabrication into hydrogels, membranes and films, porous sponges, nanofibers, microspheres and nanoparticles, and 3D-printed constructs, each interacting with tissue differently and serving both regenerative medicine and drug delivery (; ; ; ). These formats provide the organizing framework for the remainder of this review: hydrogels and injectable systems are examined in the section on hydrogels and injectable materials, implant coatings in the section on coatings and surfaces, and polymer composites and bioinks in the section on functionalization and composites (; ). From promise to practice: Barriers and the need for guidelines Translating chitosan from in vitro promise to clinical use remains difficult for several reasons: raw-material variability in MW and DD undermines reproducibility and scale-up (; ); tightly controlled laboratory parameters are hard to maintain industrially, raising cost (); and regulatory requirements are stringent, since depending on formulation a chitosan product may be a medical device or an advanced therapy medicinal product (ATMP), each demanding rigorous proof of quality, safety, and efficacy (; ). For chitosan specifically, raw-material traits drive the entire design chain: DD and MW govern processing and final porosity, mechanics, degradation, and cytocompatibility, so batch-to-batch shifts (e.g., 75% vs. 90% DD) yield divergent, artifact-prone results unless characterization is strictly controlled and consistently reported (; ; ). Harmonized guidelines for raw-material characterization, manufacturing, and standardized functional assays are therefore urgently needed; a minimum reporting set for chitosan biomaterials is proposed in the Conclusions (). Crucially, natural origin does not guarantee clinical safety or regulatory acceptance: validation of purity and endotoxin content, assessment of residual immunogenicity, storage stability, and trained research practice are all essential (; ; ). Variability in raw-material sourcing and supply chains can further exacerbate batch-to-batch differences in chitosan quality. Pharmaceutical- or biomedical-grade material requires additional deproteinization, endotoxin-reduction, and batch-consistency testing beyond industrial-grade chitosan, reinforcing that DD, MW, and purity must be treated as manufacturing-controlled specifications rather than as reported post hoc characterization values. Beyond empirical formulation screening, machine-learning-assisted approaches are increasingly applied to biomaterial property prediction and biomanufacturing-process optimization across tissue engineering more broadly (; ). Chitosan-specific applications of these methods remain rare in the current literature, representing an open methodological gap rather than an established design paradigm for this polymer. Marketed and clinically investigated chitosan-based products Chitosan has reached clinical translation, although the maturity of this translation remains strongly application-dependent. The most established examples are concentrated in hemostatic and wound-care devices, whereas fewer chitosan-based platforms have progressed to cartilage repair, peripheral nerve repair, or in situ surgical hydrogels (). Regulatory status and clinical evidence should be considered separately. In the United States, clearance through the 510(k) pathway indicates that the Food and Drug Administration (FDA) has determined a device to be substantially equivalent to a legally marketed predicate device and permits its commercial distribution. Accordingly, products following this pathway are described here as FDA-cleared rather than FDA-approved, and clearance itself should not be interpreted as evidence of clinical superiority (). Hemostasis represents the most extensively translated application of chitosan-based medical devices. HemCon Bandage and subsequent HemCon, ChitoFlex, and ChitoGauze configurations received multiple FDA 510(k) clearances, and clinical experience includes both military use and vascular-access hemostasis (; ; ). In a randomized-order crossover study involving 50 hemodialysis patients, hemostasis within 4 min was achieved in 86% of HemCon-treated access sites compared with 72% treated with conventional gauze (). Celox provides additional comparative human evidence: in a randomized trial of 160 patients with penetrating limb injuries, hemostasis within 5 min was achieved in 51.3% of patients treated with Celox-coated gauze compared with 32.5% treated with conventional gauze, with significantly lower blood loss in the Celox group (; ). Clinical performance, however, cannot be generalized across products or indications. In a prehospital study of 104 patients with bleeding scalp wounds, Axiostat reduced mean time to hemostasis from 18.56 ± 5.04 min with conventional cotton gauze to 4.68 ± 1.04 min, with successful hemostasis in 94% and 74% of patients, respectively (). By contrast, the prospective R3A study evaluating Axiostat for transradial access-site hemostasis was terminated prematurely after 41 patients because radial artery thrombosis occurred in 19.5% (8/41), despite successful hemostasis in approximately 78% of cases (). These contrasting findings illustrate an important translational principle: clinical performance belongs to a defined final device used under defined anatomical, procedural, and exposure conditions and should not be extrapolated from chitosan as a polymer class. Wound-care products extend clinical translation beyond immediate bleeding control. KA01, a nonwoven dressing composed of 100% chitosan fibers, was evaluated in a multicenter randomized clinical trial involving 90 patients. After 4 weeks, wound-area reduction was greater with the chitosan dressing than with conventional Vaseline gauze (65.97% ± 4.48% versus 39.95% ± 4.48%), and pain scores were lower (; ). MaxioCel is an FDA-cleared chitosan wound dressing for which a randomized, open-label multicenter comparison with the carboxymethylcellulose dressing Aquacel Extra has been registered (NCT05312762); no peer-reviewed outcome publication from this trial was identified during the present verification (; ). In contrast, the cited FDA submissions for SURECELL and Foundation Dermal Regeneration Scaffold products rely predominantly on nonclinical performance, biocompatibility, sterilization, and related testing, with clinical testing not required to establish substantial equivalence for Foundation DRS + Duo (; ). These examples reinforce that regulatory clearance and the strength of direct human efficacy evidence represent distinct dimensions of clinical translation. Cartilage repair provides comparatively robust randomized human evidence for a chitosan-based regenerative scaffold. In an international multicenter randomized controlled trial involving 80 patients, BST-CarGel, a chitosan-based scaffold mixed with autologous whole blood and applied in conjunction with microfracture, resulted in greater lesion filling and repair-tissue T2 relaxation times closer to native cartilage than microfracture alone at 12 months (). Longitudinal MRI analysis demonstrated that these structural differences persisted over 5 years. However, both groups showed substantial improvement in Western Ontario and McMaster Universities Osteoarthritis Index scores, without a significant between-group difference in patient-reported clinical outcomes (). Thus, the available evidence supports a sustained MRI-defined structural advantage but does not establish long-term superiority in patient-reported clinical benefit. Translation to peripheral nerve repair requires particular care in distinguishing between device clearance, nerve-gap bridging, and adjunctive use of chitosan tubes around primary nerve coaptation. Reaxon Plus is an FDA-cleared Class II chitosan nerve cuff indicated for repair of peripheral nerve discontinuities where gap closure can be achieved by flexion of the extremity (). A registered clinical study comparing the Reaxon Nerve Guide with autologous nerve grafting for digital nerve defects (NCT02459015) was terminated before planned completion (). Separately, a bicentric randomized controlled trial involving 74 patients evaluated an additional chitosan nerve tube around primary microsurgical repair of traumatic sensory nerve lesions and reported improved short-term sensory recovery (). Long-term follow-up of this randomized cohort subsequently demonstrated increased pain and impaired sensory outcomes in selected tube groups, with persistent implant remnants detected by magnetic resonance neurography at up to 5 years (). These findings demonstrate that an early regenerative advantage should not be assumed to translate into durable clinical benefit and highlight the importance of long-term degradation and tissue-response data for resorbable nerve-guidance materials. Chitogel provides a further example of translation beyond conventional topical dressings. The Chitogel Endoscopic Sinus Surgery Kit is included in the Australian Register of Therapeutic Goods as a Class III medical device (). In a randomized controlled study involving 40 patients undergoing endoscopic sinus surgery, the chitosan–dextran gel reduced mean time to hemostasis from approximately 10 min in untreated control sites to 2 min and significantly reduced postoperative adhesion formation (). A subsequent blinded randomized trial demonstrated reduced postoperative ostial stenosis compared with untreated control sites (). Further clinical investigation has evaluated Chitogel alone and in combination with therapeutic adjuvants following endoscopic sinus surgery (). More recently, Deferiprone–Chitogel was evaluated in a single-arm Phase I pilot study involving 20 patients undergoing lumbar decompression surgery. This first-in-human spinal study primarily supported short-term safety and feasibility; because it lacked a concurrent control group and was not designed to establish antifibrotic efficacy, clinical efficacy remains to be determined in larger controlled trials (). Collectively, the clinical landscape remains markedly asymmetric. Translation is most advanced for systems in which the principal therapeutic function remains predominantly material-driven, including hemostasis, exudate management, wound coverage, and structural guidance. By contrast, growth-factor-, extracellular-vesicle-, cell-, and bioink-based chitosan systems discussed later in this review remain predominantly preclinical. As functional complexity increases, the translational bottleneck extends beyond polymer processing to include final-product identity, potency, release behavior, manufacturing reproducibility, sterilization, long-term material fate, and regulatory classification. Because regulatory clearances, trial status, and commercial availability may change over time, current status should be confirmed against the relevant regulatory or clinical-trial database. Raw material - Source, parameters, and variability Chitosan is derived from chitin, a biopolymer abundant in arthropod exoskeletons and some fungal cell walls. Industrially, it is obtained mainly from marine by-products, particularly shrimp and crab shells, which contain approximately 15%–30% chitin together with proteins and CaCO3. For medical-grade applications, however, marine by-products used as chitin sources require controlled sourcing, processing, and rigorous quality assessment to ensure consistency and safety (; ; ). Chitin is purified by demineralization (acid, typically HCl) and deproteinization (strong base such as NaOH) to minimize ash and protein content, and is subsequently deacetylated, converting N-acetyl-D-glucosamine units into D-glucosamine units to produce chitosan (; ; ). Crustacean sources offer high chitin content and mature extraction technology () but are seasonal and require removal of marine allergens (). Fungal alternatives (e.g., Mucor, Rhizopus, and higher basidiomycetes), whose walls contain chitin covalently linked to β-glucan and partly deacetylated by endogenous deacetylases (; ), allow year-round bioreactor cultivation free of mineral impurities and animal proteins, avoiding shellfish-allergen risk (; ); their drawbacks are lower chitin content (10%–20% dry weight), more complex separation from glucans, and limited yields at higher cost (; ; ). The source of chitosan also influences its physicochemical properties, with crustacean-derived chitosan typically showing a higher MW, reaching up to several hundred kDa, but a lower DD, whereas fungal chitosan is usually more highly deacetylated, approximately 85%–90%, and has a lower MW, as illustrated by reported values of DD approximately 71% and MW approximately 354 kDa for crustacean chitosan versus DD approximately 85% and MW approximately 70 kDa for fungal chitosan (; ; ; ). Impact of deacetylation route on chitosan structure and variability Deacetylation removes acetyl groups from N-acetylglucosamine units; once DD exceeds ∼50% the polymer becomes acid-soluble and is termed chitosan (). Two routes are used: chemical and enzymatic (). Chemical route Purified chitin is treated with 40%–50% NaOH at 100 °C–150 °C, often under pressure; alkaline hydrolysis cleaves amide bonds, while acidic media are avoided because they cleave glycosidic bonds (; ). Temperature, reaction time, alkali concentration, and the number of treatment cycles control both DD and MW, as increasing any of these parameters generally increases DD while accelerating depolymerization and reducing MW, with repeated cycles leading to a particularly marked decrease in MW (; ; ). Deacetylation is non-uniform, creating acetyl-rich “hot spots” and a heterogeneous GlcNAc/GlcN distribution that can limit solubility despite high average DD, while chain scission broadens the MW distribution (; ; ). An N2 atmosphere or NaBH4 can protect the backbone at added cost (), and microwave-assisted processing shortens reaction times to minutes at comparable DD (). Despite its environmental burden, the chemical route remains dominant for its simplicity and throughput (). Enzymatic route Chitin deacetylases (CDA; EC 3.5.1.41) from fungi such as Mucorales catalyze N-deacetylation under mild aqueous conditions (∼40 °C–50 °C, neutral pH) that minimize glycosidic cleavage, giving higher MW, narrower distributions, more uniform structures, and DD tunable by enzyme dose and time (; ; ). CDAs act processively, forming block-like deacetylated sequences that influence solubility and bioactivity (). Efficiency is limited because enzymes attack only accessible crystal surfaces, requiring pretreatment (partial hydrolysis or milling); reported DD is often 60%–80% (occasionally 84%–90%) at modest yields, so research focuses on enzyme engineering and process optimization for biomedical-grade control (; ; ). Source- and process-dependent variability and the two routes are summarized in . Importantly, the deacetylation route should therefore be regarded not only as a production step but also as a source of process-dependent variability in the final chitosan material. Differences in DD, MW, molecular-weight distribution, and acetylation pattern generated during processing may subsequently affect physicochemical properties, biological performance, and batch-to-batch reproducibility. Controlling and reporting these process-dependent attributes is therefore essential for the standardization of chitosan intended for biomedical applications. Structural and physicochemical properties of chitosan Chitosan is a linear β-1,4-linked copolymer of 2-amino-2-deoxy-D-glucopyranose (GlcN) and N-acetyl-D-glucopyranose (GlcNAc). It therefore represents a family of polymers that differ in the GlcN/GlcNAc ratio and chain length (; ; ). The degree of deacetylation (DD), defined as the GlcN fraction, distinguishes chitosan from chitin, with chitosan generally defined by DD values above 50% (). A higher DD provides more protonatable -NH2 groups, which confer acid solubility, cationic character, and stronger antibacterial activity and tissue adhesion. In contrast, low-DD materials are poorly soluble and generally less bioactive (; ; ). Commercial chitosan grades typically span DD values of 70%–95% () and MW values from 10 to >1,000 kDa (). MW governs viscosity, mechanical strength, and biodegradation. Accordingly, high-MW chitosan forms more robust films and hydrogels, whereas low-MW chitosan and chitooligosaccharides are more soluble and permeable, but mechanically weaker and more rapidly degraded. The optimal MW is therefore application-dependent (; ; ). Biomedical design must therefore balance bioactivity, biocompatibility, and controlled biodegradation: materials that persist too long can trigger chronic reactions, whereas overly rapid degradation may compromise structural integrity (; ). High-DD/high-MW chitosan may be advantageous in applications requiring greater structural stability, whereas lower-MW or partially acetylated forms may be preferable for drug delivery and soft-tissue applications requiring greater solubility and faster resorption (; ). A third determinant is the pattern of acetylation, together with polydispersity. Two samples with identical DD may differ in solubility and bioactivity because random pattern of acetylation disrupts crystallinity and promotes dissolution, whereas block-like sequences form hydrophobic domains that hinder dissolution. Chemical routes usually produce irregular, mosaic-like PA, while enzymatic routes generate more regular sequences. Specific acetylation motifs may also modulate biological responses, including immune-related effects (; ; ). Solubility of chitosan and the influence of acid type As a free base, chitosan is insoluble in neutral water because intermolecular hydrogen bonding stabilizes its crystalline structure; it dissolves only when its amino groups (pKa ≈ 6.3–6.5) are protonated under acidic conditions, the resulting charge repulsion enabling solvation (; ). Typical solvents are dilute organic acids (acetic, formic, lactic, citric) or mild inorganic acids such as 0.1 M HCl, with acetic acid most common because chitosan acetates are biocompatible and easily neutralized (). Strong mineral acids can promote hydrolysis and leave residual acid or salt species that alter pH, osmolarity, and cytocompatibility and must be removed (). A milder alternative is CO2-assisted dissolution: compressed CO2 generates carbonic acid in situ, protonating -NH2 groups without persistent acidic residues to yield neutral, biocompatible solutions or hydrogels; this minimizes washing, enables direct tissue application with low irritation, and is validated as a bioink component (; ; ). Chemical modifications of chitosan Native chitosan’s poor neutral-pH solubility and limited functionality drive chemical modification at -NH2/-OH groups to improve solubility or add functions such as antimicrobial or conductive properties (; ; ). Quaternization yields permanently cationic quaternary ammonium salts such as N,N,N-trimethyl chitosan (TMC), water-soluble near neutral pH with stronger mucoadhesion and membrane permeability for mucosal drug/vaccine delivery, though high quaternization can raise cytotoxicity, especially at low MW (; ; ). Carboxymethylation attaches -CH2-COOH to give amphoteric carboxymethyl chitosan that swells or partly dissolves at neutral-to-basic pH, used in hydrogels and drug carriers (; ). Hydrophobic modification or copolymerization with fatty acids or poly (ε-caprolactone) produces amphiphilic systems that self-assemble into micelles or nanoparticles for hydrophobic drugs, while O-alkylation broadens solvent solubility (; ; ). These routes enable the tuning of solubility, functional-group availability, and mechanical properties (), but the introduction of foreign groups may reduce biocompatibility or increase cytotoxicity and immunogenicity. Because complete removal of residual reagents used during chemical modification, including iodomethane in methylation/quaternization and monochloroacetic acid in carboxymethylation, is essential but costly, many modified chitosans remain at the in vitro or preclinical stage (; ; ). The major routes and their translational constraints are summarized in . Purity, endotoxin control, and medical-grade quality requirements Chitosan intended for biomedical use must meet stringent purity standards, since source- and process-derived impurities, including proteins, bacterial endotoxins, solvent or reagent residues such as NaOH and acids, heavy metals, pigments such as astaxanthin, other polysaccharides such as fungal β-glucan, and unreacted chitin, can affect biocompatibility, reproducibility, and safety (; ; ). Proteins/allergens Crustacean proteins such as shrimp tropomyosin are potent allergens, so chitosan should be essentially protein-free; modern extraction (repeated deproteinization, enzymatic proteolysis) reduces protein below 0.1%, and well-purified chitosan has shown no protein bands and no immunological events in seafood-sensitized individuals using chitosan dressings (; ; ). Endotoxins Lipopolysaccharide (LPS) cause strong pyrogenic responses, so permissible levels are very low (e.g., <0.1 EU/mg for implants) (). Crustacean chitosan can acquire LPS during waste fermentation or poor sterility (), and in fungal chitosan β-glucans interfere with the Limulus amebocyte lysate (LAL) test (factor G activation), making endotoxin-specific recombinant Factor C (rFC) preferable (). Robust purification is achievable: iterative acid-dissolution/base-precipitation with exhaustive washing yielded endotoxin-free chitosan (); a chloroform-washed, pH 9-10 precipitated, autoclaved, CO2-redissolved protocol lowered LPS by ∼88–98% while preserving MW (); and an optimized four-step NaOH protocol reduced endotoxin up to 100-fold while maintaining DD and MW (). Mineral residues Crustacean-derived chitosan may retain residual mineral salts, predominantly calcium compounds, when demineralization is incomplete. Ash content is therefore commonly used as an indicator of mineral contamination; values above 1% may indicate insufficient demineralization, whereas pharmacopoeial specifications generally require ash contents below 1%, with typical values of approximately 0.2%–0.5% (; ). Heavy metals The concentrations of potentially toxic elements, particularly As, Cd, Hg, and Pb, must remain below accepted pharmacopoeial limits. Their control is particularly important for biomedical-grade chitosan because contamination may originate from the biological source material or from processing (; ). Moisture content Chitosan is hygroscopic and typically contains approximately 8%–12% equilibrium moisture. Because water content can influence material mass, storage stability, and the reproducibility of physicochemical characterization, moisture should be controlled and reported as a quality parameter (; ). Quality requirements Medical-grade chitosan must ensure consistent DD, appropriate MW, minimal impurities, and proven biocompatibility via standardized International Organization for Standardization (ISO)/FDA tests, with validated demineralization, deproteinization, decolorization, endotoxin reduction, reagent removal, and sterility/bioburden control confirmed per batch; for medical devices, only certified medical-grade material with a certificate of analysis, full traceability, and Good Manufacturing Practice (GMP)/ISO 13485 compliance should be used (; ; ). Sterilization method and its effect on chitosan properties For chitosan biomaterials intended to be supplied sterile, sterilization should be treated as a material-defining processing step rather than a neutral final operation, since its consequences depend on the method, physical state of chitosan, hydration, formulation composition, and processing dose (). Across the studies summarized in , no single method emerges as universally superior: γ-irradiation and electron-beam processing cause dose-dependent chain scission that scales with dose and physical state; steam autoclaving is compatible with some formulations but can substantially degrade chitosan solutions within minutes; ethylene oxide better preserves bulk structure in dry formats but is not chemically inert at the surface; and low-temperature approaches such as nitrogen plasma or supercritical-CO2 processing can avoid these trade-offs but introduce their own formulation-specific considerations. Sterilization method and dose should therefore be selected and validated for the final chitosan formulation, with post-sterilization testing focused on the attributes that determine its intended function. Mechanisms of chitosan interaction with cells and host tissues Physicochemical determinants of chitosan bioactivity Chitosan’s biological behavior is set by MW, DD, acetylation pattern, polydispersity, purity, residual impurities, endotoxin content, and formulation format; materials sharing an average DD can still differ in charge density, crystallinity, solubility at physiological pH, lysozyme susceptibility, and protein interactions, producing divergent cellular responses even in the same cell line (; ). DD determines the fraction of protonatable amino groups, whereas the distribution of acetylated residues, rather than the average DD alone, governs lysozyme-mediated cleavage, degradation rate, and persistence at implant sites (; ). MW shapes viscosity, diffusion, particle formation, and the dominant mode of action of chitosan, ranging from solution-based effects for low-MW polymers to surface- or scaffold-based functions for high-MW polymers (; ). Because chitosan is only partially protonated at physiological pH, its interactions are highly environment-dependent. Acidic exudate, endosomal compartments, and inflammatory microenvironments can increase electrostatic binding, whereas neutral pH and physiological salt concentrations screen charge and shift the dominant effects toward surface-mediated behavior. Claims based on acidic media, dilute solutions, or serum-free buffers should therefore not be directly extrapolated to blood-contacting or implanted systems. Crosslinking adds complexity, as adverse responses attributed to “chitosan” may stem from residual aldehydes, photoinitiators, unreacted methacrylate, acidic solvents, or extractables; mechanistic studies should therefore report chitosan chemistry, crosslinking, residual-crosslinker control, extractables, sterilization, and post-sterilization changes (; ). Purity is equally decisive: even medium-MW chitosan can carry enough endotoxin to induce tumor necrosis factor (TNF-α) in peripheral blood mononuclear cell (PBMC) co-culture, and fungal or plant-derived inputs add β-glucan that interferes with LAL assays unless glucan-blocking or rFC methods are used, so credible immunological claims require endotoxin quantification, removal, spike-recovery, TLR4 blockade, and orthogonal testing (; ; ; ; ; ). Protein adsorption and biomolecular corona formation Most chitosan biomaterials do not contact cells as pristine polymers. Upon exposure to biological fluids, including plasma, serum, exudate, synovial fluid, saliva, mucus, or interstitial fluid, their surfaces rapidly adsorb proteins, glycoproteins, lipids, salts, and ECM components. Cells therefore interact with a dynamic biointerface, commonly termed a protein corona for particles, but conceptually relevant also to films, fibers, gels, and scaffolds (). Although the cationic character of chitosan favors the adsorption of anionic proteins, corona composition is shaped by MW, DD, hydrophobic acetylated domains, surface texture, porosity, swelling, pH, ionic strength, protein concentration, and competitive adsorption. This adsorbed layer defines the effective ligand landscape presented to cells, which may respond to albumin, fibrinogen, immunoglobulins, complement fragments, vitronectin, fibronectin, or apolipoproteins rather than to chitosan itself (). Folate-chitosan nanoparticles showed serum-source-dependent coronas that altered targeting, and hyaluronic-acid coating reduced corona-associated immunogenicity, indicating that many “chitosan” responses are interfacial properties of the formulated material (; ). Complement effects are especially relevant for injectable or blood-contacting formats, where opsonization can proceed through corona-associated proteins rather than recognition of the polymer itself (). The practical implication is that chitosan should not be tested only in serum-free conditions unless the clinical use is also protein-free: experiments should distinguish unconditioned, serum/plasma-conditioned, and ECM-coated chitosan, using corona proteomics or controlled serum comparisons for particles and protein pre-coating for scaffolds to separate polymer effects from protein-mediated ones (; ). Mucoadhesion, epithelial interactions, and membrane-level effects Mucoadhesion is among the best-supported chitosan biointerface phenomena: protonated amines bind anionic mucin residues (sialic acid- and sulfate-bearing glycans), with hydrogen bonding, chain interpenetration, hydration, and hydrophobic domains as secondary contributors (). It should not be overgeneralized, because mucins differ by anatomical site, glycosylation, hydration, microbial environment, and disease, and binding measured with purified, gastric, porcine, or synthetic mucin may not predict behavior at human nasal, ocular, oral, intestinal, vaginal, or wound surfaces; MW, DD, crosslinking, and particle formation further shift residence time and convert soluble adhesion into particle or gel retention (). Chitosan-mediated, reversible opening of epithelial tight junctions is mechanistically supported and linked to defined intracellular pathways (; ). However, this effect is context-limited, requiring soluble or partially soluble cationic chitosan, suitable pH, limited ionic screening, and accessible epithelium. Barrier-opening data from nasal or intestinal delivery should therefore not be extrapolated to dermal, bone, cartilage, or intramuscular implants. Membrane-level effects are also formulation-dependent. Cationic chitosan can perturb membranes, glycosaminoglycans, and vesicle surfaces. In nanoparticles, positive charge can promote uptake, but also hemolysis, complement opsonization, and clearance, whereas in hydrogels or films the same charge may be buried or neutralized. Membrane interactions should therefore be reported together with zeta potential measured in the actual biological medium, rather than in water. The defensible summary is that chitosan can prolong residence at wet or mucus-rich interfaces and transiently modulate epithelial barriers under specific conditions, properties most relevant to topical, ocular, oral-mucosal, periodontal, and nasal delivery rather than to mineralized-tissue implants. Blood and host-tissue interactions Hemostasis is one of the most clinically visible properties of chitosan. It arises from several concurrent mechanisms, including electrostatic erythrocyte aggregation, platelet adhesion and activation, fluid absorption, concentration of clotting components, tissue adhesion, and plug formation. Therefore, hemostatic efficacy depends not only on polymer chemistry, but also on porosity, fiber size, swelling capacity, and contact mechanics. It should not be attributed to chitosan alone (; ). Blood compatibility is not a single endpoint. A dressing intended for external hemorrhage may benefit from rapid blood cell aggregation, whereas an intravascular coating or injectable particle must avoid thrombosis, complement and platelet activation, and embolism. Thus, the same cationic interactions that are useful in topical hemostatic materials may be unacceptable in intravascular applications. Blood interactions should therefore always be interpreted in relation to the intended contact type, duration, anatomical site, and regulatory category. The role of complement remains debated. Early studies reported alternative-pathway activation of C3 and C5, but not C4, by chitin and chitosan (). Later studies in human plasma and serum found binding of C3, C5, and factor B without direct activation, and attributed C5a generation in coagulating whole blood to platelet and thrombin activity rather than direct complement triggering (). Other work indicates that the physicochemical state of chitosan, including solubility and acetylation homogeneity, can influence these outcomes (). A conservative interpretation is that chitosan can bind complement proteins and participate in complement-coagulation cross-talk under specific conditions, but the general statement that chitosan activates complement is too broad. Complement should therefore be assessed using pathway- and activation-specific markers rather than inferred from protein binding alone (; ; ). Inflammatory responses are similarly context-dependent. Acute cell recruitment may be inseparable from hemostasis in a dressing, but the same response may promote fibrosis and capsule formation around an implant. Degradation products, adsorbed proteins, residual acetic acid, crosslinker residues, endotoxin, β-glucans, and sterilization-induced changes can all distort cytokine readouts. For this reason, single-time-point inflammatory assays are insufficient to characterize the biological response to chitosan-based materials. Innate immune response A key in vivo study showed that porous chitosan scaffolds with different degrees of acetylation induced distinct macrophage polarization profiles, linking a specific polymer parameter to host response and providing one of the stronger mechanistic anchors for chitosan immunobiology (). However, this relationship should not be interpreted as a response to polymer chemistry in isolation. At the biomaterial interface, macrophages encounter not only the chitosan itself but also a complex interfacial environment comprising adsorbed proteins, material-derived debris, degradation products, and local injury-associated signals. Nevertheless, polarization claims require caution. Many studies rely on limited M1/M2 marker panels, short culture periods, non-human cell lines, non-physiological media, and poorly characterized chitosan batches. Moreover, the binary M1/M2 framework oversimplifies biomaterial-induced inflammation, where macrophage phenotype is shaped by phagocytosis, hypoxia, stiffness, debris, and cytokine gradients. Therefore, an M1 or M2 claim is credible only when MW, DD, acetylation, endotoxin content, β-glucan contamination, sterilization, architecture, and temporal phenotype are described (; ; ). Endotoxin is a major confounder. Native chitosan can induce TLR4-dependent TNF-α production that disappears after purification, which undermines broad receptor-level claims when endotoxin is not controlled. Similarly, reported TLR4 signaling by chitosan oligosaccharides should be interpreted cautiously, since trace endotoxin can reproduce the same effect (; ). More specific mechanisms have also been reported. Chitosan can activate inflammasome pathways under endotoxin-minimized conditions, suggesting some degree of intrinsic innate immune activation. However, this response depends on particle size, cellular uptake, lysosomal stress, solubility, acetylation, and dose. Soluble oligomers, nanoparticles, and porous scaffolds should therefore not be assumed to share a single mechanism (). Neutrophil interactions are less well resolved, but are likely relevant to wound dressings and infected defects. They remain under-quantified, particularly with respect to NET formation, neutrophil phenotype, myeloperoxidase activity, and neutrophil-to-macrophage transition. Finally, the foreign-body reaction is not intrinsic to the polymer alone. Implant size, shape, pore size, mechanical mismatch, roughness, degradation rate, and vascular access all influence giant-cell formation, fibrosis, and vascularization. Chitosan-specific conclusions are therefore weak unless geometry and architecture are controlled (). Cell-specific interactions relevant to regeneration Fibroblasts and keratinocytes Fibroblast and keratinocyte responses are widely cited in the context of wound healing, but they usually reflect the behavior of the whole formulation rather than chitosan alone. Relevant formulation variables include hydration, stiffness, adhesive peptides, gelatin or collagen blending, residual acid, pore architecture, antimicrobial additives, and growth-factor loading. For example, peptide-modified chitosan hydrogels can accelerate repair, but such findings primarily demonstrate the value of added integrin-binding cues rather than intrinsic pro-regenerative activity of chitosan itself (). Keratinocyte responses are also tissue- and formulation-specific. Chitosan-based systems may support re-epithelialization by maintaining moisture, reducing microbial burden, limiting fluid loss, or delivering bioactive factors, and some models show signaling changes, such as ERK activation in corneal epithelium. However, such results should not be directly transferred across epithelial tissues (). To isolate a polymer-intrinsic effect, studies should compare chitosan-based systems with matched non-chitosan dressings of similar moisture content, porosity, stiffness, degradation profile, and antimicrobial performance, a level of control that few studies achieve. Endothelial cells and angiogenesis The general statement that chitosan is pro-angiogenic is not defensible. Chitosan scaffolds can support endothelial adhesion and tube formation when stiffness, porosity, hydration, and protein adsorption are appropriate. However, angiogenic outcomes may also arise from VEGF retention, heparin-mimetic functionalization, wound hypoxia, inflammation, or pore architecture (). Some derivatives and biological contexts are instead associated with anti-angiogenic effects. For example, carboxymethyl and other modified chitosans have been studied in settings where angiogenesis suppression is desirable, indicating that the direction of the response depends on derivative chemistry and biological context (). The strongest evidence comes from systems with an explicit mechanism, such as sulfated chitosan acting as a heparin-mimetic regulator of VEGF signaling. In such cases, the active material is a chemically modified glycosaminoglycan-mimetic polymer with growth-factor-binding properties. This is more mechanistically rational than attributing angiogenic effects to unmodified chitosan, but it also requires more detailed safety, reproducibility, and manufacturing characterization (). Osteoblasts, chondrocytes, and MSCs Osteoblast, chondrocyte, and mesenchymal stromal/stem cell (MSC) studies dominate the regenerative chitosan literature, particularly in bone and cartilage applications. However, these cells respond to many simultaneous cues, including adsorbed serum proteins, calcium phosphate or hydroxyapatite fillers, stiffness, pore architecture, degradation products, ionic composition, growth factors, and induction media. Therefore, lineage outcomes are often driven by the composite scaffold and culture medium rather than by chitosan alone (). DD has been linked to protein adsorption and osteogenic response; however, a higher DD is often accompanied by a lower MW as a consequence of polymer-chain degradation during deacetylation. MW should therefore be considered as a potential confounding parameter when interpreting DD-dependent osteogenic responses. Consequently, the statement that higher DD promotes osteogenesis should be avoided unless MW, crystallinity, roughness, and protein adsorption are considered. In composite bone scaffolds, the mineral phase often provides the dominant osteoconductive cue, while chitosan contributes processability, porosity, drug binding, or degradation control (; ). In cartilage applications, chitosan is typically combined with collagen, gelatin, hyaluronic acid, methacrylated networks, kartogenin, growth factors, or extracellular vesicles. In these systems, stiffness, swelling, oxygen tension, transforming growth factor (TGF-β) signaling, mechanical loading, and inflammatory cytokines are often decisive. Such formulations should therefore be interpreted as composite delivery or instructive platforms rather than chitosan-only chondrogenic materials (). MSC studies require additional caution because MSCs are donor-dependent and heterogeneous. Chitosan-associated changes in adhesion, survival, paracrine secretion, or differentiation markers may not predict in vivo potency. Translational products should therefore be evaluated as combined scaffold-cell constructs under clinically relevant conditions rather than inferred from cell behavior on plastic (). Degradation and bioactivity of degradation products Chitosan degrades in mammalian tissues mainly through lysozyme and related enzymes, including N-acetyl-β-D-glucosaminidase. However, degradation rate and degradation products depend on MW, DD, acetylation pattern, crystallinity, hydration, crosslinking, and the accessibility of acetylated sequences. Degradation is therefore enzymatic, interfacial, and tissue-dependent, rather than predictable from chemical structure alone, as is often assumed for ester-based synthetic polymers (; ; ). The acetylation pattern is particularly important because lysozyme requires suitable acetylated sequences for cleavage. As a result, two chitosans with similar average DD may degrade at different rates. Crosslinking, mineral phases, or dense scaffold architecture can further limit enzyme access, meaning that mass loss measured only in phosphate-buffered saline (PBS) is insufficient to predict in vivo residence time (; ). Degradation products may be bioactive, but this claim requires specification. Chitosan oligosaccharides can interact with immune, epithelial, and microbial systems, but their effects depend on chain length, acetylation, purity, endotoxin contamination, and dose. Moreover, local oligosaccharide concentrations generated by a slowly degrading scaffold may be far lower than those used in soluble-oligomer experiments, so these two settings should not be treated as equivalent (). Practically, degradation should be matched to the intended regenerative window. Short-term degradation may be suitable for removable hemostatic dressings, whereas early bone repair may require temporary mechanical stability. Degradation-coupled behavior may be useful for growth-factor or extracellular vesicle (EVs) release, while cartilage applications may require longer residence. Accordingly, degradation should be tested in enzyme-containing, protein-rich, and mechanically relevant media rather than in simple buffer alone (; ; ). In vitro, in vivo studies, and clinical observations In vitro studies are useful for mechanistic analysis, but they often overpredict regenerative performance. Serum-free assays, non-physiological pH, supra-clinical polymer concentrations, uncontrolled endotoxin, absence of competing proteins, short time points, and immortalized cell lines can exaggerate cationic membrane effects, uptake, cytokine induction, or adhesion. In vivo, tissue-level complexity can substantially change these responses. Bleeding, clot formation, protein adsorption, degradation, microbial burden, immune infiltration, vascularization, mechanical loading, and surgical injury may reverse in vitro impressions. A material that appears pro-inflammatory in macrophage culture may support repair by accelerating hemostasis and reducing contamination, whereas a material that appears cytocompatible may induce fibrosis if its architecture or degradation profile is inappropriate. Interpretation should therefore focus on the trajectory of the tissue response and the final tissue outcome rather than on single mechanistic labels. Clinical evidence is strongest for topical wound and hemostatic applications, but remains device- and indication-specific. For example, a multicenter RCT comparing a chitosan-derivative hydrogel paste with a commercial hydroactive gel showed granulation improvement in both groups without clear superiority, indicating that plausible preclinical biology does not necessarily translate into superior clinical outcomes (). A credible chitosan mechanism should therefore be stated conditionally. A defined chemistry, in a defined format, under defined exposure conditions, produces a defined biointerface and tissue response. This framing replaces universal labels such as “biocompatible” or “pro-regenerative” with parameterized and testable claims. The principal chitosan-host mechanisms, their key material determinants, representative evidence, and translational implications are summarized in . Antimicrobial properties: Soluble polymer versus final biomaterial Chitosan is widely studied as an antimicrobial agent. Its cationic amino groups interact electrostatically with anionic microbial membranes, disrupting membrane integrity and potentially causing cell lysis. This activity is strongly influenced by DD and MW (; ; ; ). However, antimicrobial activity is not an intrinsic and universal property of every chitosan-containing material. It depends on the physicochemical state of the polymer, including whether chitosan is soluble and protonated, incorporated into a biomaterial, crosslinked, or immobilized on a surface (; ; ). Higher DD increases amino-group density and may therefore enhance antimicrobial activity (). Nevertheless, many chitosan hydrogels and xerogels show reduced or absent activity compared with pure chitosan. This is because soluble chitosan, particularly under acidic conditions that promote protonation, can directly contact microbial cells, whereas formulated systems may restrict chain mobility, reduce amino-group accessibility, or alter the local pH and ionic environment (; ; ; ; ). Formulation effects further complicate this relationship. Additives may shield positive charge, modify swelling, or limit direct microbial contact, meaning that the mere presence of chitosan does not guarantee retained antimicrobial activity (; ; ; ). MW is another important variable. Lower-MW chitosan is more active in some systems, whereas higher-MW chitosan is more effective in others. Reported MIC values therefore span several orders of magnitude, and effective concentrations may exceed clinically feasible doses in some settings. Physiological pH and ionic strength can also reduce protonation and activity, while low chitosan content or suboptimal DD may weaken efficacy (; ; ; ; ; ). Crosslinked or surface-bound systems should be evaluated separately. In these formats, antimicrobial performance depends on surface charge density, wettability, swelling, roughness, amino-group accessibility, and direct microbial contact. Strong crosslinking may reduce activity by consuming amino groups or restricting polymer mobility (; ; ). Because microbial susceptibility also varies by organism, antimicrobial studies should report chitosan source, DD, MW, concentration, solubility state, solvent, final pH, ionic strength, strain, inoculum, exposure time, method, formulation, crosslinking, sterilization, and whether chitosan is soluble, entrapped, crosslinked, or surface-bound (; ; ; ; ). This level of reporting is necessary to distinguish genuine antimicrobial activity from formulation- or assay-dependent artifacts. Chitosan should therefore be regarded as a condition-dependent antimicrobial biomaterial whose performance must be validated for each final formulation rather than assumed from composition alone () (; ). Applications of chitosan in medical biomaterials and parameter-dependent performance Chitosan is a versatile feedstock for diverse biomaterial formats, including tissue-engineering scaffolds, hydrogels, implant coatings, nanoparticle and microsphere drug-delivery systems, and bioactive dressings. In each format, the alignment of DD, MW, solubility, and purity with the intended functional requirement is decisive (; ; ; ; ; ). For three-dimensional scaffolds used in bone, cartilage, or skin applications, raw-material parameters strongly influence performance. Such scaffolds are commonly produced by lyophilization, electrospinning, 3D printing, or casting of crosslinked sponges. MW mainly determines mechanical behavior. Longer chains generally increase strength, medium MW, approximately 100–300 kDa, can balance strength and processability, whereas very high MW increases viscosity and may impair uniform pore formation. DD modulates cell and protein interactions, with higher DD increasing charge density, adhesion, and protein adsorption, but also potentially increasing brittleness after hydration. Bone scaffolds commonly use chitosan with approximately 80%–90% DD, whereas DD values below 50% produce a more chitin-like and poorly wettable material (; ; ; ; ; ; ; ; ). DD and acetylation pattern also tune lysozyme-mediated degradation. In general, increasing DD reduces the abundance of acetylated sequences available for lysozyme-mediated cleavage, while higher MW can further reduce the rate of enzymatic degradation. However, acetylation pattern, crystallinity, crosslinking and scaffold architecture can substantially modify these trends. Consequently, long-term residence cannot be assigned to a specific DD range alone and should be determined for the final formulation under application-relevant conditions (; ). However, biological responses remain parameter- and context-specific. Higher MW favored proliferation in one model, whereas lower MW improved bacterial penetration in another, indicating that there is no universal “best” chitosan (; ; ; ; ). To improve mechanical properties, chitosan scaffolds are often crosslinked, for example, with glutaraldehyde or genipin, or blended into composites such as chitosan-collagen and chitosan-alginate systems. Crosslinking depends on the availability of amino groups, and therefore on DD, while MW influences network density and processability. Rigorous reporting and standardization of these parameters are essential for reproducibility (; ; ; ; ; ). Taken together, DD and MW should be considered as application-specific design variables rather than universal indicators of nterpre performance. therefore provides a cross-application comparison of representative DD and MW ranges, degradation or residence nterpre, and the principal design trade-offs relevant to regenerative biomaterials. The values should be nterpreter as representative design windows rather than universal specifications, because degradation and functional performance are additionally governed by acetylation pattern, crystallinity, crosslinking, hydration, formulation composition, and final material architecture (; ; ). Chitosan-based hydrogels and injectable materials Chitosan hydrogels are three-dimensional, water-swollen networks used as hydroactive wound dressings, drug-delivery systems, and injectable implants for minimally invasive repair (; ). They can form through physical interactions, including temperature- or pH-driven sol-gel transitions, such as neutralization of acidic chitosan solutions with basic phosphate, or through chemical crosslinking. Multivalent anions, such as tripolyphosphate (TPP), can also induce ionic gelation, a mechanism widely used both for hydrogel formation and for the preparation of chitosan nanoparticles (; ; ). Polymer parameters govern hydrogel rheology, gelation kinetics, and degradation. High-MW chitosan forms cohesive gels, but can hinder mixing and injectability. For this reason, medium-MW chitosan, approximately 100–300 kDa, is often preferred for injectable systems. Higher DD increases the number of protonated amino groups and can increase crosslink density, leading to faster and stiffer TPP-based gelation, although such gels may also be more brittle. Lower-DD analogues usually form softer and more elastic, but mechanically weaker, networks (; ; ; ; ). In wound care, chitosan hydrogels can maintain a moist environment in chronic or hard-to-heal wounds, including burns and diabetic ulcers. They can also absorb exudate and provide antibacterial or pro-healing functionality, depending on formulation. These applications typically require moderately crosslinked, elastic gels that adhere to the wound, remain stable for several days, and can be removed without additional tissue damage (; ; ). As drug carriers, chitosan hydrogels can control the release of antibiotics, cytostatics, and growth factors. Stronger crosslinking and higher DD or MW generally slow diffusion, whereas lower-DD and more hydrophobic chitosans may bind hydrophobic drugs and prolong release. This tunability enables profiles such as gradual growth-factor release in angiogenic wound-healing gels (; ; ). Animal models support the regenerative potential of selected chitosan hydrogels compared with controls. For example, carboxymethyl chitosan dressings have been reported to reduce scarring and accelerate burn re-epithelialization. Overall, native chitosan, its derivatives, including N,O-carboxymethyl and trimethyl chitosan, and tuned crosslink densities provide a versatile hydrogel toolkit for wound care, drug delivery, and minimally invasive regenerative applications (; ; ; ; ). Chitosan coatings and surfaces Chitosan coatings can act as bioactive and antibacterial layers on implants, as well as nanoscale layer-by-layer (LbL) assemblies on stents and culture scaffolds (; ). As an adhesive polycation, chitosan can be deposited on metals, glass, and polymers to form thin films. On titanium, such coatings have been reported to improve osteoblast adhesion and provide antibacterial activity (; ). Material parameters determine coating stability and function. MW influences film thickness and continuity, with higher-MW chitosan generally producing more continuous but thicker films. In LbL systems, chitosan with MW values of approximately 50–150 kDa is often used to obtain nanometric layers. DD determines surface charge density, with higher DD providing more -NH3 + groups that can strengthen electrostatic interactions with microbial membranes. However, coatings are generally more bactericidal against Gram-positive than Gram-negative species, and MW-dependent activity trends remain strain- and model-dependent. MW must therefore be sufficient to resist erosion, while DD should support antimicrobial performance without excessive biological activation (; ; ; ; ). The required balance also depends on the implant setting. On vascular stents, moderate surface charge may support controlled platelet interactions and antithrombotic sealing, whereas excessive DD can promote aggregation. On orthopedic hardware, chitosan coatings can carry growth factors such as bone morphogenetic protein (BMP-2) or TGF-β. In this context, higher DD may favor binding of anionic proteins, while sufficient MW helps resist premature dissolution (; ; ). In vivo studies illustrate the application-specific nature of these effects. Chitosan-coated titanium screws showed faster osseointegration, reduced biofilm formation, and maintained biomechanics compared with bare titanium, with nano-hydroxyapatite further improving outcomes. In another context, partially depolymerized chitosan suture coatings released fragments and resorbed over approximately 2 weeks, matching the re-epithelialization window (; ; ). Practical design conclusions The practical implications of these parameters can be consolidated into a translational decision framework. In this framework, source selection, DD and MW specification, purity and endotoxin control, solvent system, crosslinking strategy, and sterilization are matched to the intended clinical function rather than chosen independently. In general, higher DD values, approximately 80%–95%, favor solubility, cationic charge, mucoadhesion, and antimicrobial activity, making them relevant for wound dressings, coatings, and gene-delivery systems. For applications requiring prolonged structural persistence, higher MW together with controlled crosslinking and sufficiently high DD may reduce enzymatic erosion; however, residence time should be experimentally established for the final formulation because acetylation pattern, crystallinity and material architecture can substantially modify DD- and MW-dependent degradation (; ). Regardless of application, purity remains a non-negotiable baseline, particularly for implantable materials, where endotoxin levels should be below 0.1 EU/mg and verified using LAL or rFC assays (; ; ; ). A full minimum reporting set is provided in the Conclusions. This framework is summarized in . Functionalization and composites of chitosan in tissue engineering Chitosan’s processability and tunable chemistry make it widely used in drug delivery, tissue-engineering scaffolds, and growth-factor delivery, with MW and DD strongly shaping how it is functionalized and how it interacts with biological systems (; ). This section critically reviews targeted functionalization and composite design for regenerative medicine. Growth factors, drugs, and extracellular vesicles Functionalization transforms chitosan from a structural matrix into a delivery and signaling platform; the central challenge is to preserve cargo bioactivity while matching release, retention, and presentation to the biological sequence of repair. Growth factors Delivery strategies and mechanistic tradeoffs Growth-factor functionalization of chitosan biomaterials should be evaluated as a problem of protein presentation, not simply protein loading. Most regenerative growth factors are dose-sensitive, structurally fragile, and context-dependent. BMP-2, VEGF, fibroblast growth factor (FGF-2), platelet-derived growth factor (PDGF), nerve growth factor (NGF), and related factors can produce desirable effects within a narrow spatiotemporal window but may cause ectopic tissue formation, aberrant vascularization, inflammation, fibrosis, or loss of efficacy if released in an uncontrolled burst. Chitosan’s cationic and hydrogel-forming properties can be useful, but only when the formulation protects the protein, controls its release, preserves bioactivity, and places the dose within a clinically plausible range (; ; ; ). The relevant design question is therefore not whether a chitosan scaffold can be loaded with a growth factor. It is whether the strategy controls (i) loading efficiency, (ii) burst release, (iii) protein denaturation during loading and sterilization, (iv) displacement by serum proteins, (v) diffusion through the scaffold, (vi) degradation-coupled liberation, and (vii) post-release bioactivity. Several chitosan-based growth-factor delivery studies have characterized cumulative release under simplified PBS conditions (; ), whereas direct assessment of the structural integrity or specific biological activity of the released protein has received considerably less attention. Such release data demonstrate formulation feasibility but, in the absence of post-release potency testing, do not by themselves establish a regenerative mechanism. Adsorption Adsorption is experimentally simple and often increases apparent loading because proteins interact with chitosan through electrostatic and hydrogen-bonding interactions. However, it is also the least controlled approach. Growth factors adsorbed to a cationic surface can desorb rapidly, become partially denatured, or be displaced by serum proteins once exposed to wound exudate, plasma, synovial fluid, or interstitial fluid. Adsorption-only designs are most defensible when the intended clinical need is short-term local exposure and when burst release is acceptable. They are less defensible for BMP-2, VEGF, or NGF delivery where uncontrolled early release can reduce efficacy or increase adverse-effect risk (). Ionic complexation and affinity-based retention Ionic complexation exploits the cationic nature of chitosan and the charge properties of proteins or polyanions to form polyelectrolyte complexes under mild aqueous conditions; the limitation is sensitivity to pH, salt concentration, competing proteins, and local degradation, so complexes stable in low-ionic-strength buffer may release rapidly under physiological conditions. This approach becomes more rational when the binding interaction is designed around the growth factor’s natural biology: for heparin-binding factors, incorporating heparin, heparan-sulfate-like domains, or sulfated chitosan can mimic extracellular matrix retention, moving the formulation from nonspecific electrostatics toward biologically informed affinity retention (; ). Heparin/chitosan systems are particularly relevant for NGF, VEGF, FGF-2, and other heparin-binding proteins, aligning release control with growth-factor biochemistry rather than nonspecific adsorption; a heparin/chitosan-NGF scaffold, for example, improved peripheral nerve regeneration in preclinical models (). Sulfated chitosan extends this logic by chemically converting chitosan itself into a heparin-mimetic material: 2-N,6-O-sulfated chitosan can manipulate VEGF-induced angiogenesis, a more mechanistically precise claim than “chitosan is pro-angiogenic,” since the active material is a sulfated derivative whose effect depends on sulfation position, charge density, MW, and VEGF interaction (). Affinity systems can reduce burst release and protect growth factors, but introduce safety and manufacturing questions: heparin source, anticoagulant activity, sulfation heterogeneity, batch consistency, and residual reagents must be controlled, and for sulfated chitosan, substitution pattern and degree of sulfation become critical quality attributes. These systems are translationally more plausible than adsorption-only platforms but require more sophisticated analytics and release-potency assays (). Affinity-based retention Heparin/chitosan systems are particularly relevant for NGF, VEGF, FGF-2, and other heparin-binding proteins. Heparin can bind and stabilize growth factors, while chitosan contributes scaffold formation, processability, and tissue adhesion. A heparin/chitosan scaffold loaded with NGF was designed to exploit electrostatic retention and improve peripheral nerve regeneration in preclinical models (). The conceptual strength of such a system is that it aligns release control with growth-factor biochemistry rather than relying on nonspecific adsorption. Sulfated chitosan extends this logic by chemically modifying chitosan itself into a heparin-mimetic material. A study of 2-N,6-O-sulfated chitosan showed that sulfation pattern can manipulate VEGF-induced angiogenesis, suggesting that modified chitosan can influence growth-factor signaling, not merely release kinetics (). This is a more mechanistically precise claim than “chitosan is pro-angiogenic.” The active material is a sulfated derivative with growth-factor-binding features, and its biological effect should be interpreted as a function of sulfation position, charge density, MW, and VEGF interaction. Affinity systems can reduce burst release and protect growth factors, but they also introduce safety and manufacturing questions. Heparin source, anticoagulant activity, sulfation heterogeneity, batch consistency, and residual reagents must be controlled. For sulfated chitosan, substitution pattern and degree of sulfation become critical quality attributes. Translationally, these systems are more plausible than adsorption-only platforms but require more sophisticated analytics and release-potency assays (). Encapsulation and nanoparticle-in-scaffold systems Encapsulation places the growth factor inside particles, microspheres, or hydrogel domains that are then integrated into a scaffold. This can reduce burst release, protect the protein during early exposure, and enable staged delivery. Chitosan/biphasic calcium phosphate scaffolds functionalized with BMP-2-encapsulated nanoparticles and arginine-glycine-aspartate (RGD) peptides illustrate a multilayer strategy: the mineral phase contributes osteoconductivity, RGD supports adhesion, and nanoparticles regulate BMP-2 presentation (). The outcome should therefore be interpreted as a composite effect, not as a chitosan-only osteogenic response. Nanoparticle-in-scaffold systems can also separate multiple biological phases. For infected bone defects, an antibacterial phase can precede an osteogenic phase; for wound healing, early hemostasis or antimicrobial action can be followed by angiogenic and matrix-remodeling cues. However, staged release is difficult to prove unless the study measures time-resolved release of each cargo under relevant conditions and demonstrates that each released cargo remains active. Covalent immobilization Covalent immobilization can improve spatial retention and reduce burst release and is particularly useful when sustained matrix-bound signaling rather than diffusional delivery is desired (; ; ; ). In chitosan-based systems, covalent growth-factor presentation has been demonstrated using several coupling strategies. BMP-2 and FGF-2 were immobilized on chitosan films through EDC/NHS-mediated coupling, with the immobilized factors retaining biological activity and promoting osteoblast- or fibroblast-associated responses compared with adsorbed growth factors (). EGF has also been photochemically immobilized on chitosan membranes using a heterobifunctional crosslinker, where the immobilized factor stimulated fibroblast proliferation (). Covalent growth-factor tethering has additionally been applied in methacrylamide-chitosan hydrogel systems to direct neural stem-cell differentiation and self-organization (). However, covalent attachment is not intrinsically advantageous. Coupling may alter protein conformation or modify residues involved in receptor recognition, and successful immobilization should therefore not be equated with retained biological activity (; ; ; ). Consequently, covalently immobilized growth factors should be evaluated using receptor-binding or cell-based functional assays in the final material configuration, particularly after immobilization, sterilization, and storage. Degradation-coupled release Degradation-coupled release is attractive for regenerative medicine because it ties cargo liberation to scaffold residence and tissue remodeling. A photocrosslinkable chitosan hydrogel containing FGF-2 demonstrated biologically active release upon degradation and improved wound healing in diabetic mice, providing an early example of this logic (). Although older, this study remains conceptually important because it did not treat release kinetics as a purely physical diffusion problem; it linked release to biodegradation and tested biological activity. Across all delivery strategies described above, the methodological baseline is the same: release should be measured in protein- and enzyme-containing media rather than PBS alone, early time-point resolution matters as much as cumulative release, and post-release bioactivity must be confirmed with a growth-factor-specific assay rather than inferred from downstream gene expression. These controls, together with the translational trade-offs of each strategy, are summarized in . Evidence for regenerative outcomes in wound healing of distinct tissues/organs Bone repair is the most common setting for BMP-2-functionalized chitosan composites. Recent systems increasingly combine antibacterial and osteogenic delivery, reflecting the clinical reality that infection and inflammation can block bone regeneration. A staged ciprofloxacin/BMP-2 nanoparticle system in a chitosan-containing scaffold illustrates this infection-first, regeneration-second design logic (). Similar sequential vancomycin/BMP-2 platforms for chronic osteomyelitis extend the concept to infected bone defects, although these remain preclinical and require careful infection-model validation (). Wound healing systems frequently use FGF-2, PDGF, VEGF, bFGF, or combinations thereof. A PDGF-AA-loaded photo-crosslinked chitosan-based hydrogel reported improved handling, hemostatic properties, and wound-healing-associated cellular behaviors (). Dual growth-factor systems such as VEGF plus bFGF attempt to reproduce the temporal complexity of wound healing, but mechanistic claims require proof that each factor remains bioactive after loading and release (). Peripheral nerve repair systems often use NGF retention through heparin/chitosan scaffolds. The biological rationale is stronger than adsorption-only approaches because NGF is a heparin-binding neurotrophic factor and Schwann-cell behavior depends on local trophic support (). Still, preclinical nerve-repair outcomes should be compared with clinically relevant nerve conduits and autograft benchmarks. A chitosan-NGF scaffold that improves a rat nerve gap model is not automatically clinically competitive. Cartilage repair research has seen a rise in the utilization of chitosan hydrogels in combination with chondrogenic small molecules, growth factors, EVs or cells. Within these systems, chitosan is often used for its ability to provide a local retention and mechanical environment rather than serving as the main chondrogenic signal. It is important for claims to distinguish between the contribution of the scaffold itself and the cargos it may contain. Furthermore, assessments should include mechanical testing, analysis of matrix quality, and consideration of the inflammatory context, rather than solely relying on the expression of chondrogenic ECM components. Drugs Strategy-by-format analysis Drug functionalization of chitosan biomaterials includes small molecules, antibiotics, anti-inflammatory agents, osteogenic drugs, analgesics, and antiseptic compounds. The design logic differs from growth-factor delivery because many drugs are more chemically stable, less structurally fragile, and easier to quantify. Nevertheless, the same translational questions apply: release in relevant fluids, dose realism, sterilization stability, storage, local toxicity, resistance risk for antibiotics, and compatibility with tissue repair. Hydrogels are suited for injectable depots and irregular defects because they can fill space, retain water, and release drug as the network swells or degrades. Films and membranes are suited for topical wounds and periodontal applications. Porous scaffolds and 3D-printed composites are more relevant for bone defects where mechanical support and local delivery are needed. Nanoparticles or microparticles within scaffolds can add a rate-limiting barrier and reduce burst release (; ). Hydrogels and injectable depots Chitosan hydrogels can act as local depots through ionic interactions, mesh-size restriction, swelling control, and degradation. Thermosensitive systems, genipin-crosslinked gels, beta-glycerophosphate formulations, carboxymethyl chitosan gels, and methacrylated chitosan networks all have different release mechanisms. Therefore, “chitosan hydrogel release” should not be treated as one technology. The critical limitation is that many hydrogel studies use release media that do not represent clinical conditions. PBS release without proteins, enzymes, pH variation, inflammatory mediators, or mechanical compression may overestimate stability or underestimate burst release. For wound, bone infection, and cartilage applications, release should be tested in media that approximate exudate, infected tissue fluid, or synovial-like environments, followed by antimicrobial, anti-inflammatory, or osteogenic potency testing of the released fraction. Infected bone defects illustrate why drug delivery and regeneration cannot be separated. Local antibiotics may reduce bacterial burden, but excessive local concentrations can impair osteoblasts, MSCs, endothelial cells, or immune resolution. Conversely, growth factors delivered before infection control may fail or worsen inflammation. Chitosan-based staged systems that release an antibiotic first and an osteogenic cue later are therefore biologically plausible (; ). A 3D-printed polylactic acid (PLA)/nano-hydroxyapatite scaffold incorporating a chitosan-vancomycin hydrogel reported sustained vancomycin release over weeks, inhibition of Staphylococcus aureus, and osteoblast compatibility (). The design is clinically relevant because local antibiotic delivery can achieve concentrations difficult to maintain systemically. However, translation requires in vivo infection models, biofilm relevance, resistance monitoring, local cytotoxicity thresholds, and comparison with established local-delivery standards. Anti-inflammatory drugs, corticosteroids, non-steroidal agents, and osteogenic small molecules can be incorporated into chitosan nanoparticles, hydrogels, or fibers. Dexamethasone sodium phosphate-loaded chitosan nanoparticles embedded in electrospun scaffolds provide an example of nanoparticle-mediated rate control within a composite scaffold (). Extracellular vesicles (EVs) Correct EV terminology The EV field has moved away from the casual use of biogenesis-based terms such as “exosomes” unless their endosomal origin has been directly demonstrated. The 2018 and 2023 Minimal Information for Studies of Extracellular Vesicles guidelines recommend using “extracellular vesicles” as a generic term, or more precise operational descriptors such as “small EVs,” “large EVs,” “CD63-positive EVs,” or “cell-derived EVs,” depending on the separation method, size range, molecular markers, and cellular source (; ). This distinction is particularly important for chitosan-based biomaterials, because many studies incorporate EV-enriched or extracellular particle preparations into hydrogels or scaffolds and then attribute the observed biological effects to EVs without sufficient evidence of vesicular identity, purity, or functional specificity. Chitosan platforms may amplify this interpretive problem. Due to its cationic and adsorptive nature, chitosan can retain not only EVs, but also protein aggregates, lipoproteins, nucleic acid-protein complexes, serum-derived particles, adsorbed growth factors, and other non-vesicular extracellular particles. Therefore, biological effects observed after release from chitosan-based matrices may result from EVs themselves, co-isolated soluble factors, serum contaminants, adsorbed bioactive molecules, or matrix-dependent release kinetics. For this reason, EV-loaded chitosan systems should be described operationally and reported with sufficient methodological detail, including the source cell type, culture conditions, serum or serum-free protocol, EV separation method, size fraction, marker characterization, purity metrics such as particle-to-protein ratio, potency assay, loading strategy, release method, and post-release EV integrity (; ; ). Fetal bovine serum (FBS) contamination is a major limitation in EV studies. Even EV-depleted serum may contain residual bovine EVs, extracellular RNA, proteins, lipoproteins, and other contaminants that can confound the interpretation of human or animal EV preparations (; ; ). Donor and source variability is also scientifically and ethically relevant. MSC-derived EVs can differ according to tissue source, donor age, disease state, passage number, culture stress, and manufacturing conditions. These variables should therefore be reported and, where possible, controlled or acknowledged as limitations. EV loading strategies in chitosan biomaterials Physical entrapment, which disperses EVs within a gel precursor before gelation, is the most common EV loading strategy because it avoids harsh conjugation chemistry and suits injectable hydrogels and dressings. However, the EV preparation is exposed to the gelation environment—shear, pH, crosslinking chemistry, photoinitiators, elevated temperature, or osmotic shifts can alter EV membrane integrity or surface proteins—so post-loading integrity must be measured rather than assumed from pre-loading size distribution alone, and released EVs should be tested for particle number, protein markers, non-vesicular contaminants, and potency (). A chitosan hydrogel dressing loaded with adipose MSC-derived vesicles, for example, reported slow release associated with chitosan degradation and improved wound repair in a rat model (), though interpretation depends on whether EV identity was operationally confirmed rather than assumed. Electrostatic adsorption can improve EV retention on chitosan fibers or particles, but may also mask surface molecules, promote aggregation, co-adsorb non-vesicular proteins, or alter biodistribution and receptor presentation: positively charged chitosan can bind negatively charged EV membranes and co-isolated proteins into aggregates that release differently from free EVs, so release curves expressed only as particle counts can be misleading unless protein release, vesicle integrity, and potency are separately assessed. Hydrogel retention and scaffold integration are translationally attractive because local EV delivery may avoid rapid clearance after injection, but the relevant potency is that of the released fraction at each time point rather than of the starting suspension—a scaffold that retains EVs too strongly may show excellent loading but poor bioavailability. This complexity increases when EVs are combined with cells: an nHA/chitosan/poly (lactic-co-glycolic acid) (PLGA) scaffold delivering adipose stem cell-derived EVs and bone marrow stem cells for bone healing is a multi-component product in which osteogenesis could arise from mineral phase, cells, EVs, or their interactions (), requiring factorial controls (scaffold alone, plus cells, plus EVs, plus both) to attribute outcomes correctly. Hybrid systems can assign distinct functions to distinct components: an immunomodulatory EV-loaded chitosan methacryloyl hydrogel combined with pro-chondrogenic microspheres frames EVs as immune microenvironment modulators and kartogenin-containing microspheres as chondrogenic drivers (), a division of labor more mechanistically defensible than attributing all repair to EVs—although using vesicles from LPS-activated macrophages raises additional safety questions around endotoxin carryover and residual activation signals. Modulation of EV retention in biomaterials Affinity-based retention via heparin/chitosan systems or sulfated chitosan is more mechanistically justified than simple adsorption, particularly for heparin-binding growth factors. Sulfated chitosan can modulate VEGF-induced angiogenesis, while heparin/chitosan scaffolds can retain NGF in nerve-repair applications (; ). Adsorption-only loading is less convincing translationally unless burst release, protein displacement, and post-release bioactivity are controlled (). Similarly, composite systems combining antibacterial and osteogenic functions may be advantageous in infected bone defects (; ; ), but release studies performed only in PBS may poorly reflect protein-rich, enzymatic, inflammatory, or mechanically loaded in vivo environments. Sterilization and storage can further alter chitosan network properties and release behavior, supporting post-sterilization evaluation of release kinetics and bioactivity (). For EV-loaded chitosan systems, retention and release should be interpreted in accordance with the 2018 and 2023 Minimal Information for Studies of Extracellular Vesicles guidelines (; ). Inadequate demonstration of vesicle identity, purity, or functional specificity may confound biological outcomes through non-EV fractions, serum-derived contaminants, co-isolated proteins, or chitosan-mediated retention effects (; ; ; ). The functionalization strategies discussed throughout this section, together with their key advantages, limitations, and translational controls, are summarized in . Peptide functionalization of chitosan-based biomaterials Why functionalize biomaterials with peptides? Chitosan can be cytocompatible and antimicrobial in suitable formulations, but it lacks the adhesive signaling motifs of the extracellular matrix (ECM), which can limit cell adhesion and differentiation (). For this reason, chitosan surfaces or bulk structures are often modified with short ECM-derived peptides, particularly the integrin-binding Arg-Gly-Asp (RGD) sequence, to provide receptor-mediated cues that guide adhesion, proliferation, migration, and differentiation (; ; ). Peptide functionalization can also be used to deliver pro-angiogenic or antimicrobial peptides. When incorporated into chitosan nanoparticles or matrices, these peptides can be released gradually, prolonging their local bioactivity (; ; ) (). Thus, peptide incorporation serves two complementary purposes: improving cell affinity through adhesive motifs and providing sustained biological signaling through therapeutic peptides. For example, RGD-modified chitosan improves cell attachment and proliferation, whereas controlled release of therapeutic peptides can support prolonged regenerative signaling (; ; ; ; ; ). Influence of molecular weight and degree of deacetylation on peptide conjugation Chitosan is a linear copolymer of glucosamine and N-acetylglucosamine whose functionalization depends mainly on MW and DD. Low-MW chitosan (here referring to oligomeric and near-oligomeric fractions, approximately below 10 kDa, at the lower boundary of the commercial MW range discussed above) dissolves and reacts more readily and can support peptide encapsulation, but it tends to form smaller and less dense particles. In contrast, high-MW chitosan hydrogels form denser networks that slow peptide diffusion and prolong release (; ). High DD, approximately 90%–95%, increases the density of protonatable amino groups and provides a greater number of primary amines available for peptide coupling. In contrast, lower DD reduces the number of available amino groups and may therefore limit the extent of covalent peptide attachment (; ; ; ). These parameters determine the coupling mechanism. In physical encapsulation, peptides are retained through electrostatic or physical entrapment. Low MW and moderate DD may favor higher porosity and faster release, whereas dense high-MW networks are more suitable for prolonged release (; ). In covalent immobilization, peptides are typically linked to free amine groups on chitosan using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide/N-hydroxysuccinimide (EDC/NHS) chemistry. Higher DD provides more reactive amines, while high MW supports a stable network that can prolong signal presentation. Cells generally distinguish adsorbed from covalently bound peptides and often respond more strongly to immobilized cues. However, DD must be optimized, because partial acetylation may leave too few available amines, while low-pH protonation can promote swelling or layer detachment (; ; ). In practice, the choice depends on peptide function, material format, and peptide stability. Slow release is usually preferable for soluble signaling peptides, whereas surface presentation is more appropriate for adhesive peptides such as RGD or serine-isoleucine-lysine-valine-alanine-valine (SIKVAV). Immobilization is typically favored in dense xerogels and coatings, while both encapsulation and immobilization can be used in soft hydrogels and bioinks. Chitosan matrices may also protect peptides from enzymatic degradation more effectively than solution-based delivery (; ; ; ; ; ). Free versus covalently bound peptides in different biomaterial forms The choice between free and bound peptide presentation should match the mode of action, exposure time, and material format. In hydrogels, free peptides can act as depot-based signals, because peptide-polymer interactions slow diffusion and help sustain local signaling concentrations. In contrast, adhesive motifs such as RGD are often best covalently immobilized, for example, using EDC/NHS chemistry, to prevent leaching and control ligand density and orientation. Covalently anchored sequences such as SIKVAV have been shown to enhance fibroblast proliferation and wound healing (; ; ; ; ). In xerogels, rehydration can readily wash out free peptides, making covalent conjugation the more robust strategy. High DD provides amines for coupling, while higher MW helps stabilize the matrix during wet-dry cycles (; ). In implant coatings, surface presentation is suitable for durable cell anchorage through stable RGD immobilization, whereas controlled diffusion is more appropriate for antimicrobial peptides. For example, gelatin-chitosan antimicrobial peptide coatings can limit infection and support osteogenesis, with release tuned by lower MW and intermediate DD, which produce a less compact network (; ; ; ). In bioinks for 3D bioprinting, chitosan can carry cells and biomolecules, while MW and DD govern rheology and network formation. Free peptides provide dynamic cues as the matrix remodels, whereas covalently tethered peptides preserve signal presentation during perfusion and extended culture. This stable presentation is often important for guiding lineage specification in pluripotent-cell bioinks (; ; ; ; ). Choosing the functionalization strategy Free and bound peptides should be viewed as complementary rather than competing strategies. Hybrid biomaterials can immobilize part of the peptide at the surface to support immediate adhesion, while encapsulating the remaining fraction for longer-term signaling during degradation. This enables staged regulation of cellular responses, from early attachment to subsequent migration and differentiation. System design should therefore match chitosan MW and DD, material format, and peptide properties (; ; ; ). These complementary roles are summarized in . Modification of chitosan by other polymers for tissue engineering applications Chitosan properties are governed primarily by MW and DD. Higher DD increases the content of cationic amine groups, solubility in mild acids, and intermolecular interactions, whereas higher MW increases chain entanglement and viscosity. Together, these parameters shape complex formation, processing behavior, and biomolecule delivery (; ; ). Because neat chitosan can be brittle, mechanically limited, and slow or pH-dependent in gelation, it is commonly blended with natural or synthetic polymers to create composites with complementary or synergistic properties (). This section reviews such modifications across four tissue-engineering formats, namely, hydrogels, xerogels, implant coatings, and 3D-bioprinting bioinks, with emphasis on how co-polymer choice, DD, and MW govern processing, compatibility, and final material properties (; ). Chitosan-polymer hydrogels Building on the DD- and MW-dependent gelation behavior established above, this section focuses specifically on how blending with a second polymer modifies chitosan hydrogel networks for soft-tissue engineering and bone filling (; ). Natural partners include gelatin, which forms polyelectrolyte complexes with protonated chitosan amines. When co-crosslinked, particularly in the presence of multivalent anions, gelatin and chitosan can form tougher hybrid networks while avoiding the dense precipitates often associated with chitosan-only crosslinking (; ; ). Anionic polysaccharides such as alginate and hyaluronic acid enable ionic crosslinking and add biofunctionality. Alginate, for example, crosslinks with Ca2+ and can stiffen chitosan-alginate complexes. Higher-DD chitosan strengthens these interactions through hydrogen bonding and ion pairing, whereas low-DD chitosan forms weaker networks unless additional crosslinking strategies are introduced (; ; ). Synthetic partners are used to tune mechanics and responsiveness. Chitosan/poly (vinyl alcohol) (PVA) double networks combine a rigid PVA crystalline phase that dissipates energy with a flexible chitosan network, resulting in highly tough hydrogels (; ). Polyethylene glycol (PEG) grafting increases chain mobility and can produce softer, injectable gels suitable for cartilage repair. Thermosensitive chitosan/poly (N-isopropylacrylamide) (PNIPAM) systems remain liquid at room temperature and gel at body temperature, enabling in situ delivery. In these systems, MW and DD influence pre-gel viscosity, gelation temperature, and mesh size (; ). In general, natural additives such as gelatin and collagen contribute cell-adhesive sites and softer matrices, whereas synthetic partners such as PVA, PEG, and PNIPAM provide mechanical reinforcement or stimulus responsiveness. Moderate MW, approximately 50–200 kDa, often provides a useful balance between processability and mechanical stability (; ; ). Chitosan-polymer xerogels Xerogels are dried polymer networks, typically porous freeze-dried sponges, used as scaffolds for skin, bone, nerve, and cartilage applications (). Pure freeze-dried chitosan sponges are biocompatible and porous, but they are usually mechanically weak and can degrade rapidly. For this reason, chitosan is commonly blended with structural polymers before drying (; ). Collagen and ECM-derived glycoproteins improve tissue mimicry. Lyophilized collagen-chitosan sponges show increased resistance to enzymatic degradation after mild crosslinking while retaining cytocompatibility. In such systems, chitosan can act as a physical or chemical crosslinking component that extends in vivo residence time, whereas collagen or gelatin supports cell adhesion and infiltration. Composites incorporating fibrinogen-binding domains have also been reported to accelerate wound closure and vascularization in full-thickness defects through combined hemostatic and antimicrobial effects (; ; ; ). Other natural partners, including silk fibroin, elastin, alginate, and glycosaminoglycans, modulate scaffold mechanics and pore architecture. Silk fibroin and elastin are particularly useful for increasing tensile strength and elasticity (). DD strongly influences microstructure. High-DD chitosan forms stronger interpolymer and hydrogen bonds, leading to smaller pores, stiffer matrices, higher crystallinity, lower swelling, and greater protein adsorption. These features may be useful for nerve conduits and load-bearing implants. Lower-DD chitosan is more hydrophobic and can produce larger, more open pores, which may be advantageous for soft tissues requiring rapid cell infiltration (; ; ). Synthetic partners add durability and processing flexibility. Polyesters such as PLGA and polycaprolactone (PCL) provide slower degradation and improved mechanical strength, while chitosan contributes hydrophilicity and biofunctionality. Because pure chitosan is difficult to electrospin, co-spinning with poly (ethylene oxide) or PCL is often used to obtain nanofiber mats. In electrospun chitosan/poly (ethylene oxide) scaffolds, approximately 85% DD balanced flexibility and osteoblast-like cell support, whereas very high DD increased brittleness and very low DD reduced cell attachment (; ; ). Chitosan-based implant coatings Composite coatings combine the bioactivity and antibacterial potential of chitosan with the mechanical or chemical stability of a partner polymer, addressing the limited adhesion and softness of pure chitosan films (; ). In polyelectrolyte multilayers, layer-by-layer assembly alternates cationic chitosan with an anionic polymer such as PAA or alginate. Chitosan/PAA multilayers incorporating chlorhexidine on silicon and titanium achieved durable and sustained antibacterial activity. In these systems, electrostatic bonding is tuned by pH and DD. Higher DD generally produces thicker, more crosslinked films with higher drug-binding capacity, whereas lower DD forms looser layers with faster release (; ; ). In blended single-layer coatings, higher DD strengthens binding to anionic partners and stiffens the film. However, polymer ratios must be optimized to obtain uniform layers. PEG grafting can introduce antifouling behavior, but excessive PEG content may weaken cell-adhesive and antibacterial effects. For bone-contacting coatings, nano-hydroxyapatite embedded in chitosan/polymer matrices can enhance osteoblast differentiation by combining organic and inorganic cues. Higher-DD chitosan may further support this function by chelating Ca2+ and binding hydroxyapatite more strongly (; ; ). Coatings should be thin but durable. Medium-MW chitosan, approximately 50–300 kDa, can form coherent and crack-free films, whereas very high MW may hinder uniform application. Near-complete DD can also reduce solubility and complicate coating preparation (; ). Properly designed multilayer or blended coatings can protect implants, deliver therapeutics, and promote tissue integration, including increased osteoblast attachment and new bone formation on chitosan-coated titanium (; ; ). Chitosan-polymer bioinks for 3D bioprinting Bioinks are biomaterial formulations, often hydrogel precursors, used in 3D bioprinting. A successful bioink must balance printability, shear-thinning rheology, post-printing fidelity, cytocompatibility, and gelation kinetics (). Chitosan is attractive because of its biocompatibility and antibacterial potential, but it is difficult to print alone because it is soluble mainly under acidic conditions and can gel or precipitate during neutralization. Therefore, it is usually blended with polymers that stabilize printing and provide complementary crosslinking mechanisms (). A common strategy is to pair chitosan with thermoresponsive or ionically crosslinkable polymers that enable rapid post-extrusion stabilization. Chitosan-gelatin-alginate inks use gelatin to support thermoreversible filament formation, chitosan to provide biofunctionality, and alginate to enable rapid Ca2+-mediated ionic crosslinking. Methacrylated gelatin can additionally provide photocrosslinking (; ; ). Chitosan is also combined with synthetic polymers such as Pluronic F127 or poly (ethylene glycol) diacrylate (PEGDA). Methacrylated chitosan co-printed with PEGDA forms photocrosslinked interpenetrating networks that combine chitosan-derived adhesion and biodegradability with rapid PEGDA curing. Cellulose nanofibers can also be incorporated to provide shear-thinning behavior followed by ionic crosslinking (; ). Performance depends strongly on MW and DD. Higher MW increases viscosity, which helps prevent cell settling and maintain filament shape. However, excessive MW, particularly above approximately 500 kDa, can impair extrusion and increase shear stress on cells. For this reason, many bioinks use chitosan in the approximate range of 100–300 kDa. High DD strengthens interactions with polyanions, supporting faster self-setting and better shape fidelity, but it can also cause premature gelation in the nozzle. Lower DD delays gelation and provides more working time, although often at the cost of reduced network strength (; ; ; ). Natural partners such as gelatin and alginate provide biocompatibility and mild crosslinking triggers. Synthetic components such as Pluronic, PEGDA, and modified chitosan provide more precise control over gelation and mechanics. Chitosan may also contribute antimicrobial support, but this function should be validated in the final printed matrix rather than inferred from the presence of chitosan alone (; ; ; ). Synthesis of composite design principles Across hydrogels, xerogels, coatings, and bioinks, complementary polymers help offset the main limitations of chitosan, including weak mechanics and processing challenges. Natural polymers such as collagen, gelatin, and alginate improve cell interactions and bioactivity, whereas synthetic polymers such as PVA, PEG, PNIPAM, PLA, and PCL provide strength, stability, and more controlled gelation (; ; ; ). DD and MW remain the two central design variables. Higher DD increases reactivity and network strength, but excessive DD can accelerate gelation, increase brittleness, or reduce solubility. Higher MW reinforces networks through chain entanglement, but overly high MW can hinder mixing, film formation, or extrusion. These parameters should therefore be selected according to the intended application. For example, approximately 80%–90% DD combined with medium MW may be suitable for tough and adhesive bone-graft hydrogels, whereas slightly lower DD or MW may be preferable for printable bioinks (; ; ; ; ). Mastering the interplay between DD, MW, and the selected polymer partner enables the design of finely tuned biomaterials for regenerative medicine. Composite strategies can produce robust double-network hydrogels, cell-friendly porous sponges, infection-resistant coatings, and printable tissue-mimicking bioinks (; ; ; ). Ethical, regulatory, and translational considerations Ethical and translational analysis of chitosan-based regenerative platforms should focus on preventable scientific harms rather than on generic statements about animal origin or natural materials. As discussed in the sections on raw-material purity/endotoxin control and on growth-factor, drug, and extracellular-vesicle functionalization above, the recurring risks are concrete and include under-characterized animal-derived inputs, residual proteins and allergens, endotoxin and β-glucan contamination, premature claims of biocompatibility or regeneration, and unvalidated extracellular-vesicle (EV) or cell potency. These concerns are not abstract, because they directly affect patient safety, reproducibility, animal welfare, and public trust (; ; ). A central point is that a biomaterial-only chitosan dressing, an antibiotic-loaded scaffold, a BMP-2-loaded hydrogel, an MSC-seeded construct, and an EV-loaded matrix are ethically and regulatorily distinct products. The ethical and evidentiary burden increases as the intended mode of action shifts from material-based function toward pharmacological, cellular, or vesicle-mediated mechanisms. Such platforms should therefore not be described simply as chitosan biomaterials (; ). From biomaterial to combination product: Why classification matters Regulatory classification depends on the components, intended use, and primary mode of action. It should be addressed early, because misclassification can lead to inadequate safety testing, unrealistic development timelines, and premature clinical claims. In the United States, combination products comprise two or more regulated components, including drug-device, biologic-device, or drug-device-biologic combinations, as well as cell-seeded or biologic-coated devices. Accordingly, a chitosan scaffold combined with BMP-2, an antibiotic, viable cells, or EVs requires combination-product analysis rather than device-only logic, with the primary mode of action guiding the regulatory pathway (; ). In the European Union, advanced therapy medicinal product frameworks cover gene therapy, somatic-cell therapy, tissue-engineered products, and combined ATMPs. A chitosan scaffold carrying viable cells may therefore fall under tissue-engineered product or combined-ATMP rules. EV products raise analogous concerns related to source, manufacturing, characterization, potency, and safety, even where they do not map cleanly onto existing categories (; ; ; ). Authors should distinguish scientific category from legal category, avoid jurisdiction-independent regulatory claims, and not imply that the food-use history of chitosan reduces the evidentiary burden for a combination product. Risk-based biocompatibility and product-specific evaluation Biocompatibility is a property of a specific final product, not of the base polymer. FDA guidance on ISO 10993-1 frames biological evaluation within a risk-management process that considers the nature and duration of body contact, materials, manufacturing, and sterilization (). The same chitosan may therefore require very different testing packages depending on whether it is used as a topical dressing, absorbable implant, injectable hydrogel, blood-contacting particle, drug depot, or cell- or EV-loaded scaffold. Relevant endpoints may include cytotoxicity, sensitization, irritation, systemic toxicity, implantation, hemocompatibility, genotoxicity, and degradation products, depending on the intended use. For animal-derived chitosan, ISO 22442-style provenance and sourcing logic should inform risk management (). For cell- or EV-containing products, scaffold biocompatibility is necessary but not sufficient. The biological component requires its own framework for identity, purity, potency, and safety (; ). Reproducibility and research integrity Reproducibility failures are themselves an ethical problem because they waste animals, misdirect funding, and risk translating artifacts of contamination, formulation, or assay design into clinical narratives. The recurrent weaknesses discussed throughout the raw-material and functionalization sections above, including missing MW and DD data, unreported acetylation pattern, unknown endotoxin or β-glucan status, undocumented sterilization, weak comparators, and EV misclassification, should be treated as research-integrity issues rather than minor reporting gaps (; ; ). These risk categories, their translational significance for chitosan specifically, and the corresponding minimum expectations for responsible reporting are summarized in . A defensible endotoxin strategy should specify the assay type. Recombinant factor C may be considered as an animal-free alternative, particularly when β-glucan interference is plausible (; ; ). The corresponding discipline is linguistic as much as experimental. Authors should avoid describing chitosan as biocompatible, pro-regenerative, or complement-activating as a universal property. Instead, they should state that a defined material, with defined characterization, produced a defined effect under defined conditions, with relevant confounders made explicit. Conclusion Chitosan has earned sustained attention in regenerative medicine because it can be processed into hydrogels, porous scaffolds, films, coatings, nanoparticles, bioinks, and composite matrices while offering chemically accessible amine groups, pH-dependent charge, enzymatic degradability, wet-tissue interactions, and cargo-binding capacity. The evidence reviewed here supports chitosan as a useful biomaterial platform, but only when it is described as a defined material in a defined formulation. General statements that chitosan is biocompatible, antimicrobial, hemostatic, immunomodulatory, or regenerative are scientifically weak unless they are bounded by DD, MW, pattern of acetylation, purity, endotoxin and β-glucan status, formulation format, dose, exposure route, and biological model. The most important translational lesson is that chitosan performance is interfacial and product-specific. Cells rarely encounter pristine polymer; they encounter a dynamic biointerface shaped by protein adsorption, mucus or blood components, salts, pH, degradation products, residual reagents, sterilization effects, and device architecture. This is particularly important for immune and blood-contacting endpoints, where endotoxin, β-glucan, complement binding, coagulation, platelet activation, and protein corona formation can substantially alter the interpretation of mechanistic studies. Similarly, antimicrobial activity demonstrated for soluble protonated chitosan should not be assumed for crosslinked hydrogels, xerogels, coatings, composites, or bioinks unless the final formulation is tested against relevant organisms under relevant pH, ionic strength, serum, and biofilm conditions. For advanced platforms, the evidentiary threshold increases. Growth-factor-loaded chitosan systems should demonstrate loading, release in relevant media, post-release bioactivity, dose realism, and sterilization stability. Drug-loaded systems should integrate antimicrobial or anti-inflammatory efficacy with host-cell compatibility and tissue-repair outcomes. EV-loaded chitosan matrices should use terminology consistent with current extracellular vesicle guidelines, characterize both input and released EV fractions, control for non-vesicular contaminants and FBS-derived material, and establish release-normalized potency. Cell-loaded constructs require donor traceability, cell-product characterization, potency in the final scaffold-cell configuration, and long-term safety considerations. Future progress will depend less on adding more chitosan formulations and more on improving comparability, quality control, and regulatory-aware design. Minimum reporting should include source, lot, DD, MW distribution, polydispersity, pattern of acetylation where feasible, residual protein, ash/metals, endotoxin testing with interference controls, β-glucan strategy when relevant, solvent and pH history, crosslinking chemistry, residual reagents, sterilization method, storage conditions, degradation testing, and final-product biological evaluation. Clinical translation will require clinically meaningful comparators, mechanism-linked potency assays, scalable manufacturing, GMP-compatible inputs, and early classification of device, combination-product, ATMP, or biologic-like regulatory pathways. Chitosan should therefore be positioned not as a universally regenerative natural polymer, but as a tunable aminopolysaccharide platform whose value lies in disciplined material definition, formulation-specific biological testing, and integration with realistic translational constraints. With standardized characterization, evidence-based claim language, and product-specific regulatory strategy, chitosan-based biomaterials can continue to contribute to regenerative medicine while avoiding the reproducibility and overstatement problems that have limited many promising preclinical technologies.